Shares of biotechnology company Ocugen, Inc. (OCGN) shares are down 11 percent on Wednesday's trading thus breaking the stock's upward trend since the past few days. The stock has been on an upward trajectory since submitting NDA for Phase 3 clinical trial of its COVID-19 vaccine candidate COVAXIN (BBV152) on October 26.

Create Account

Dark

chart

exchange

Check out our Level2View

Shares of biotechnology company Ocugen, Inc. (OCGN) shares are down 11 percent on Wednesday's trading thus breaking the stock's upward trend since the past few days. The stock has been on an upward trajectory since submitting NDA for Phase 3 clinical trial of its COVID-19 vaccine candidate COVAXIN (BBV152) on October 26.

RTTNews | Nov 3, 2021 11:31AM EDT

11:31 Wednesday, November 3, 2021 (RTTNews.com) - Shares of biotechnology company Ocugen, Inc. (OCGN) shares are down 11 percent on Wednesday's trading thus breaking the stock's upward trend since the past few days. The stock has been on an upward trajectory since submitting NDA for Phase 3 clinical trial of its COVID-19 vaccine candidate COVAXIN (BBV152) on October 26.

Currently at $13.92, the stock has traded between $0.27 and $18.77 during the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3238992/ocugen-rally-ends-shares-slip-11.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved